Group 1 - Banqiao Qiancheng signed a significant contract with Mango Film and Television for a total amount of 372 million yuan, accounting for 50.65% of the company's audited main business income for 2024 [1] - The contract allows Mango Film and Television to use the new media and traditional media broadcasting rights for related film and television works globally, positively impacting Banqiao Qiancheng's financial status and operating performance in 2025 and beyond [1] - Jingwei Huikai plans to sell its wholly-owned subsidiary Changsha Yushun for 112 million yuan, which will no longer be included in the consolidated financial statements after the transaction [1] Group 2 - Minsheng Health's subsidiary received a patent for a strain of lactic acid bacteria that significantly improves sarcopenic obesity, although it has not yet been applied to the company's products [2] - Dafu Technology intends to transfer 27% of its subsidiary Shenzhen Peitian Intelligent Manufacturing Equipment Co., Ltd. for 192 million yuan, maintaining a controlling stake post-transaction [3] - Feilong Co. received orders for high-power electronic water pumps for data centers from a well-known global power electronics provider [4] Group 3 - Yatai Co. was selected as a supplier for a foreign brand's EPB project, with a total sales amount of approximately 680 million yuan over a five-year lifecycle [5] - Gansu Energy's 1 million kilowatt wind-solar integrated project has received approval, representing over 10% of the company's installed capacity by the end of 2024 [6] - Jilin Aodong's subsidiary received approval for a drug supplement application for "Tang Le Capsule," used to treat symptoms related to diabetes [7] Group 4 - Shanshui Technology plans to invest 6 billion yuan in a new chemical materials project, expected to generate an annual output value of 8 billion yuan upon completion [8] - Dazhu CNC's H-share issuance application has been accepted by the China Securities Regulatory Commission [9] - Zhujiang Beer announced the resignation of its chairman due to retirement age, with a new chairman elected on the same day [10] Group 5 - Longkun Technology won a bid for a waste collection service project worth 21.57 million yuan, with a service period of one year [11] - Zhongnan Culture plans to provide financial support of up to 20 million yuan to its subsidiary for daily operational needs [12] - Shangfeng Cement's investment in a company applying for an IPO on the Sci-Tech Innovation Board has been accepted [13] Group 6 - Chuanheng Co. received a patent for a system and method for harmless treatment of phosphorus tailings [14] - Toukeng Life's seven medical device registration applications have been accepted, covering various diagnostic fields [15] - Xingqi Eye Medicine's clinical trial for a new eye gel has commenced with the first subject enrolled [16] Group 7 - Jiebang Technology plans to provide financial support of up to 60 million yuan to its subsidiary for operational needs [17] - Shenzhen Airport reported a passenger throughput of 5.54 million in May, a year-on-year increase of 15.67% [18] - Wan'an Technology received a cash dividend of 30 million yuan from its wholly-owned subsidiary [19] Group 8 - Jiuchuan Bio received a medical device registration certificate for a cystatin C assay kit [20] - Hongqiang Co. obtained a safety production license for its subsidiary, marking the official production of a new project [21] - Xiangtan Electric plans to issue convertible bonds totaling 487 million yuan [22] Group 9 - Guangwei Composite signed a supplementary material procurement contract worth 658 million yuan [23] - Jichuan Pharmaceutical announced a comprehensive tender offer starting June 18, with a price of 26.93 yuan per share [24] - Aerospace Rainbow plans to distribute cash dividends of 0.60 yuan per share [25] Group 10 - Industrial Bank plans to distribute cash dividends of 1.06 yuan per share, totaling 22.433 billion yuan [26] - China Automotive Research will repurchase and cancel 230,800 restricted shares due to the retirement of original incentive objects [27] - Annie Co. announced abnormal stock trading fluctuations but confirmed no significant changes in its operations [28] Group 11 - Giant Network confirmed no undisclosed significant matters following abnormal stock trading fluctuations [29]

证券代码：000623 证券简称：吉林敖东 公告编号：2025-032 吉林敖东药业集团股份有限公司 关于控股子公司获得药品补充申请批准通知书 的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，吉林敖东药业集团股份有限公司（以下简称"公司"）控股子公司吉 林敖东药业集团延吉股份有限公司（以下简称"延吉药业"）收到国家药品监督 管理局下发的"糖乐胶囊"的《药品补充申请批准通知书》。现就相关情况公告 如下： 一、《药品补充申请批准通知书》的主要内容 1．糖乐胶囊 药品通用名称：糖乐胶囊 剂型：胶囊剂 规格：每粒装0.3g 注册分类：中药 受理号：CYZB2500952 通知书编号：2025B02585 原药品批准文号：国药准字Z20025227 上市许可持有人名称：吉林敖东药业集团延吉股份有限公司 上市许可持有人地址：吉林省延吉市高新技术开发区长白路389号 生产企业名称：吉林省德商药业股份有限公司 生产企业地址：吉林省辉南县经济开发区北一街 申请内容：其他：变更糖乐胶囊（国药准字Z20025227）的上市许可持有人， 主体由吉林省德商药 ...

吉林敖东药业集团股份有限公司（以下简称"公司"）于 2016 年 7 月 15 日 召开的 2016 年第一次临时股东大会审议通过了《<吉林敖东药业集团股份有限公 司员工持股计划（草案）>及其摘要》的议案，具体内容详见 2016 年 6 月 30 日、 2016 年 7 月 16 日在《中国证券报》《上海证券报》《证券时报》《证券日报》 及巨潮资讯网（http://www.cninfo.com.cn）披露的相关公告。 鉴于公司第一期员工持股计划存续期将于 2025 年 12 月 8 日届满，根据中国 证券监督管理委员会《关于上市公司实施员工持股计划试点的指导意见》、深圳 证券交易所《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规 范运作》相关规定，上市公司应当在员工持股计划届满前六个月公告即将到期的 员工持股计划所持有的股票数量及占公司股本总额的比例，现将相关情况公告如 下： 一、本次员工持股计划存续期内的持股情况 1.公司于 2016 年 7 月 15 日召开的 2016 年第一次临时股东大会审议通过了 《<吉林敖东药业集团股份有限公司员工持股计划（草案）>及其摘要》的议案， 具体内容详见 ...

Core Viewpoint - Jilin Aodong (000623) announced that its subsidiary Yanbian Pharmaceutical has obtained 25 listings for traditional Chinese medicine formula granules, which will positively impact the company's expansion in this business segment and enhance its core competitiveness [1] Group 1: Company Developments - Yanbian Pharmaceutical has received a total of 525 listing certificates for traditional Chinese medicine formula granules as of the announcement date [1] - The newly obtained products include Jiu Bi Ying, American ginseng, Huoxiang, and fried rice sprouts [1] Group 2: Market Impact - The sales performance of the newly listed products may be influenced by changes in the market environment, indicating potential uncertainties [1] - The short-term impact on the company's overall performance is not expected to be significant [1]

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 近日，吉林敖东药业集团股份有限公司（以下简称"公司"）控股子公司吉 林敖东延边药业股份有限公司（以下简称"延边药业"）获得25个《中药配方颗 粒上市备案凭证》，现就相关情况公告如下： 证券代码：000623 证券简称：吉林敖东 公告编号：2025-030 吉林敖东药业集团股份有限公司 关于控股子公司获得中药配方颗粒上市备案凭证 的自愿性信息披露公告 一、《中药配方颗粒上市备案凭证》的主要内容 根据《中华人民共和国药品管理法》《中华人民共和国药品管理法实施条例》 等法律和法规的规定，对延边药业的以下产品予以备案： | 序号 | 名称 | 备案号 | | --- | --- | --- | | 1 | 救必应配方颗粒 | 上市备字2225000023000 | | 2 | 西洋参配方颗粒 | 上市备字2225000036000 | | 3 | 藿香配方颗粒 | 上市备字2225000066000 | | 4 | 炒稻芽配方颗粒 | 上市备字2225000067000 | | 5 | 六月雪（六月雪）配方颗粒 | 上市 ...

Summary of Jilin Aodong Pharmaceutical Group Conference Call Company Overview - Jilin Aodong Pharmaceutical Group Co., Ltd. was established in 1957 and has developed into a holding company with multiple subsidiaries in pharmaceuticals, medical research, and sales, among others [3][4][6] - The company operates under a "pharmaceutical + finance" dual-driven model and has a comprehensive supply chain involving planting and breeding bases [3][4] Key Points from the Conference Call Governance and Operational Efficiency - The company has received multiple governance honors in 2024, including recognition for its board practices, which have contributed to improved operational performance [6] - Continuous improvement of corporate governance structures and internal controls has been emphasized to ensure accurate information disclosure and enhance investor returns [6] Multi-Drive Development Model - The company is focused on a "pharmaceutical + finance + health" multi-drive development model, enhancing synergy and resource sharing across its various segments [7][8] - Marketing strategies have been optimized to align with national pharmaceutical policies, enhancing the efficiency of academic promotion and channel management [8] Market Expansion and Product Development - Jilin Aodong is actively exploring international markets while maintaining steady growth in its pharmaceutical core business [9][10] - The company has optimized its chemical drugs and retail pharmacy businesses, leveraging e-commerce platforms for sales growth [10][11] Financial Performance - In 2024, the company reported a revenue of 2.61 billion yuan, a decrease of 24.31% year-on-year, while net profit increased by 6.27% to 1.55 billion yuan [13][14][36] - The traditional Chinese medicine segment remains the largest contributor, accounting for 61.50% of total revenue [14][31] R&D and Innovation - R&D investment in 2024 was approximately 99.91 million yuan, a decrease of 29.69% from the previous year, with a focus on balancing R&D spending with cost control [32][33] - The company is committed to modernizing traditional Chinese medicine through innovative research and development, particularly in areas like cancer and cardiovascular diseases [33][42] Brand and Market Positioning - The "Aodong" brand has been recognized as a famous Chinese trademark and has a brand value of approximately 11.68 billion yuan [15][16] - The company aims to enhance its market share through targeted marketing strategies and maintaining high product quality [15][43] Challenges and Strategic Responses - The company faces challenges such as industry competition and product homogenization, which it addresses through differentiated marketing strategies and quality management [43] - Plans for 2025 include focusing on core products, optimizing shareholder returns, and enhancing market confidence through effective management practices [38][39] Future Outlook - The company is optimistic about growth in 2025, focusing on expanding its core product lines and enhancing R&D capabilities to meet market demands [41][42] - Jilin Aodong aims to leverage its strengths in traditional Chinese medicine and health products to capture emerging market opportunities [41][42] Additional Important Information - The company has implemented a cash dividend plan for 2024, distributing 3 yuan per 10 shares, balancing shareholder returns with capital needs [20][21] - The first quarter of 2025 saw a revenue of 623 million yuan, a decline of 27.71%, but net profit surged by 259.75% due to investment gains [22][23] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Jilin Aodong's operational strategies, financial performance, and future growth plans.

Core Insights - The company is focusing on expanding its online sales through major e-commerce platforms like JD.com, Taobao, and Pinduoduo, while also enhancing its O2O (Online to Offline) business model to seek new growth points [1] - A new pharmaceutical marketing management center has been established to strengthen professional service capabilities, with measures in place to revitalize slow-moving and unsold products [1] - The company aims to create a closed-loop ecosystem in the pharmaceutical industry by enhancing product supply from its manufacturing segment and improving customer retention through membership and pharmaceutical services [1] Sales and Marketing Strategy - The company is consolidating its market position for key products like injection-grade ribonucleic acid II through a clinical-to-terminal sales model and optimizing performance assessments for clinical personnel [1] - Plans include hosting marketing summits and academic seminars to cover hospital terminals and promote resource coverage nationwide [1] - The company is accelerating market penetration for selected products through centralized procurement and aims to achieve sales growth with newly approved products [2] Research and Development - The company is actively exploring traditional Chinese medicine and conducting research in various therapeutic areas, including cancer, kidney disease, diabetes, and cardiovascular diseases [3] - Multiple generic drug approvals have been obtained, including phosphoric acid oseltamivir capsules and others, indicating a steady progression in R&D projects [3] Technological Integration - The company is leveraging AI technology to optimize drug screening and clinical trial design, moving towards a smart manufacturing model that emphasizes high quality and efficiency [4] - A marketing reform initiative has been launched to establish a unified command and collaborative marketing system, enhancing strategic coordination and operational awareness across the organization [4]

Governance and Management - Jilin Aodong has received multiple governance honors, including the 2024 Excellent Board Practice Case, highlighting its commitment to corporate governance and operational performance improvement [2][3] - The company has established a robust governance structure and internal control management system to ensure accurate and complete information disclosure [2][3] Financial Performance - In 2024, the company achieved a revenue of CNY 261,057.51 million, a decrease of 24.31% compared to the previous year, while net profit attributable to shareholders increased by 6.27% to CNY 155,139.31 million [7][14] - The cost of the pharmaceutical segment decreased by 12.56% year-on-year, indicating effective cost management strategies [6][14] Business Segments - The three main business segments—traditional Chinese medicine, chemical pharmaceuticals, and retail pharmacy—generated a combined revenue of CNY 227,376.10 million, accounting for 87.10% of total revenue [7][11] - The traditional Chinese medicine segment alone contributed CNY 160,554.13 million, representing 61.50% of total revenue [7][9] Marketing and Sales Strategies - The company is enhancing its marketing system by integrating online sales through major e-commerce platforms and optimizing its offline stores for O2O business [5][11] - A focus on core product matrix development and strategic marketing initiatives has been implemented to improve sales performance and market penetration [10][11] Research and Development - In 2024, R&D investment amounted to CNY 99,909,053.79, a decrease of 29.69% from the previous year, with a focus on balancing R&D spending and cost control [17][19] - The company is actively pursuing innovation in traditional Chinese medicine and exploring new product development in various therapeutic areas [19][20] Shareholder Returns - The company plans to distribute a cash dividend of CNY 3 per 10 shares for 2024, reflecting a commitment to shareholder returns while balancing operational needs [12][13] - A three-year shareholder return plan has been established to enhance dividend frequency and optimize payout ratios [12][13] Challenges and Future Outlook - The company faces challenges such as declining revenue and increasing accounts receivable relative to revenue, prompting a focus on risk management and operational efficiency [16][21] - Future strategies include enhancing core product market share, expanding into international markets, and leveraging AI technology for operational improvements [20][21]

北京市京都（大连）律师事务所 法律意见书 北京市京都（大连）律师事务所 关于吉林敖东药业集团股份有限公司 召开 2024 年年度股东大会 之 法 律 意 见 书 致：吉林敖东药业集团股份有限公司 北京市京都（大连）律师事务所（以下简称"本所"）接受吉林敖东药业集团股 份有限公司（以下简称"公司"）的委托，指派本所律师 王秀宏、杨姗姗 出席公司 2024 年年度股东大会（以下称"本次股东大会"）。本所律师根据《中华人民共和国 公司法》（以下简称《公司法》）、中国证监会《上市公司股东会规则》（以下简称 《股东会规则》）和《吉林敖东药业集团股份有限公司章程》（以下简称《公司章程》） 的相关规定，就公司本次股东大会的召集与召开程序、出席会议人员与召集人的资格、 议案的提出、表决程序和结果等事宜的合法性、有效性进行见证并出具法律意见。 公司保证和承诺其已经向本所律师提供了为出具本法律意见书所必需的、真实的 原始书面材料、电子邮件；有关副本材料、复印件与原件一致；公司对所提供的文件 资料的合法性和有效性承担法律责任。 本所律师根据对事实的了解和对法律的理解发表法律意见。 本所及本所律师对所出具的法律意见书承担法律责任。 ...

证券代码：000623 证券简称：吉林敖东 公告编号：2025-029 吉林敖东药业集团股份有限公司 2024年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形。 2、本次股东大会无变更以往股东大会已通过决议的情形。 一、会议召开和出席情况 （一）召开情况 1、会议召开的时间： （1）现场会议召开的时间：2025年5月23日（星期五）下午14:00开始。 （2）网络投票时间： 2、召开地点：吉林省敦化市敖东大街2158号公司办公楼六楼会议室 3、表决方式：现场投票与网络投票相结合的方式 4、召集人：吉林敖东药业集团股份有限公司董事会 5、主持人：董事长李秀林先生 6、会议召开的合法、合规性：本次股东大会会议召开符合有关法律、行政 法规、部门规章、规范性文件、深圳证券交易所业务规则和《公司章程》的规定。 （二）出席情况 1、出席现场会议及网络投票的股东及股东授权委托代表合计 509 人，代表 股份数 418,189,662 股，占公司有表决权股份总数 1,172,381,587 股（有表决 权股 ...